메뉴 건너뛰기




Volumn 18, Issue 33, 2012, Pages 5273-5293

Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease

Author keywords

Antiplatelet therapy; Coronary artery disease; Diabetes mellitus; Platelets

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CILOSTAZOL; CLOPIDOGREL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 1 INHIBITOR; ELINOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEMOGLOBIN A1C; PADGEM PROTEIN; PHOSPHODIESTERASE III; PICOTAMIDE; PRASUGREL; PROSTAGLANDIN E1; PURINERGIC P2Y12 RECEPTOR; RAMATROBAN; RIDOGREL; TERUTROBAN; TICAGRELOR; TICLOPIDINE; VORAPAXAR;

EID: 84870020093     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803251916     Document Type: Article
Times cited : (21)

References (257)
  • 1
    • 0035856920 scopus 로고    scopus 로고
    • Global and societal implications of the diabetes epidemic
    • Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
    • (2001) Nature , vol.414 , pp. 782-787
    • Zimmet, P.1    Alberti, K.G.2    Shaw, J.3
  • 2
    • 0031752685 scopus 로고    scopus 로고
    • Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections
    • King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
    • (1998) Diabetes Care , vol.21 , pp. 1414-1431
    • King, H.1    Aubert, R.E.2    Herman, W.H.3
  • 3
    • 7544224325 scopus 로고    scopus 로고
    • The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart
    • Euro Heart Survey Investigators
    • Bartnik M, Rydén L, Ferrari R, et al. Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880-90.
    • (2004) Eur Heart J , vol.25 , pp. 1880-1890
    • Bartnik, M.1    Rydén, L.2    Ferrari, R.3
  • 4
    • 7244252855 scopus 로고    scopus 로고
    • Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative
    • CRUSADE Investigators
    • Bhatt DL, Roe MT, Peterson ED, et al. CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292: 2096-104.
    • (2004) JAMA , vol.292 , pp. 2096-2104
    • Bhatt, D.L.1    Roe, M.T.2    Peterson, E.D.3
  • 5
    • 23744491212 scopus 로고    scopus 로고
    • Quality of care by classification of myocardial infarction: Treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction
    • National Registry of Myocardial Infarction Investigators
    • Roe MT, Parsons LS, Pollack CV Jr, et al. National Registry of Myocardial Infarction Investigators. Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Arch Intern Med 2005; 165: 1630-6.
    • (2005) Arch Intern Med , vol.165 , pp. 1630-1636
    • Roe, M.T.1    Parsons, L.S.2    Pollack Jr., C.V.3
  • 6
    • 2342466734 scopus 로고    scopus 로고
    • Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030
    • Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
    • (2004) Diabetes Care , vol.27 , pp. 1047-1053
    • Wild, S.1    Roglic, G.2    Green, A.3    Sicree, R.4    King, H.5
  • 7
    • 77956379970 scopus 로고    scopus 로고
    • Diabetes and the platelet: Toward new therapeutic paradigms for diabetic atherothrombosis
    • Morel O, Kessler L, Ohlmann P, Bareiss P. Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis 2010; 212: 367-76.
    • (2010) Atherosclerosis , vol.212 , pp. 367-376
    • Morel, O.1    Kessler, L.2    Ohlmann, P.3    Bareiss, P.4
  • 8
    • 0030790437 scopus 로고    scopus 로고
    • What cardiologists need to know about diabetes
    • Webster MW, Scott RS. What cardiologists need to know about diabetes. Lancet 1997; 350 Suppl 1: SI23-8.
    • (1997) Lancet , vol.350 , Issue.1 SUPPL. 1 , pp. 23-28
    • Webster, M.W.1    Scott, R.S.2
  • 9
    • 0032560807 scopus 로고    scopus 로고
    • Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
    • Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
    • (1998) N Engl J Med , vol.339 , pp. 229-234
    • Haffner, S.M.1    Lehto, S.2    Rönnemaa, T.3    Pyörälä, K.4    Laakso, M.5
  • 11
    • 0141615827 scopus 로고    scopus 로고
    • Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II
    • Lüscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003; 108: 1655-61.
    • (2003) Circulation , vol.108 , pp. 1655-1661
    • Lüscher, T.F.1    Creager, M.A.2    Beckman, J.A.3    Cosentino, F.4
  • 12
    • 0034730110 scopus 로고    scopus 로고
    • Impact of diabetes on longterm prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry
    • Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on longterm prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102: 1014-9.
    • (2000) Circulation , vol.102 , pp. 1014-1019
    • Malmberg, K.1    Yusuf, S.2    Gerstein, H.C.3    Brown, J.4    Zhao, F.5    Hunt, D.6    Piegas, L.7    Calvin, J.8    Keltai, M.9    Budaj, A.10
  • 15
    • 0141615827 scopus 로고    scopus 로고
    • Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I
    • Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527-32.
    • (2003) Circulation , vol.108 , pp. 1527-1532
    • Creager, M.A.1    Lüscher, T.F.2    Cosentino, F.3    Beckman, J.A.4
  • 16
    • 0035499206 scopus 로고    scopus 로고
    • Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control
    • Osende JI, Badimon JJ, Fuster V et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307-12.
    • (2001) J Am Coll Cardiol , vol.38 , pp. 1307-1312
    • Osende, J.I.1    Badimon, J.J.2    Fuster, V.3
  • 17
    • 0027254691 scopus 로고
    • Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus
    • Takada Y, Urano T, Watanabe I, Taminato A, Yoshimi T, Takada A. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1993; 71: 405-15.
    • (1993) Thromb Res , vol.71 , pp. 405-415
    • Takada, Y.1    Urano, T.2    Watanabe, I.3    Taminato, A.4    Yoshimi, T.5    Takada, A.6
  • 18
    • 84859995395 scopus 로고    scopus 로고
    • A novel mechanism for hypofibrinolysis in diabetes: The role of complement C3
    • Hess K, Alzahrani SH, Mathai M, et al. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 2012; 55: 1103-13.
    • (2012) Diabetologia , vol.55 , pp. 1103-1113
    • Hess, K.1    Alzahrani, S.H.2    Mathai, M.3
  • 19
    • 37249068049 scopus 로고    scopus 로고
    • Platelet activation and atherothrombosis
    • Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
    • (2007) N Engl J Med , vol.357 , pp. 2482-2494
    • Davì, G.1    Patrono, C.2
  • 20
    • 14744287439 scopus 로고    scopus 로고
    • Pathobiology and cell interactions of platelets in diabetes
    • Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005; 2: 16-23.
    • (2005) Diab Vasc Dis Res , vol.2 , pp. 16-23
    • Stratmann, B.1    Tschoepe, D.2
  • 21
    • 23644433510 scopus 로고    scopus 로고
    • Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-5.
    • (2005) Diabetes , vol.54 , pp. 2430-2435
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3
  • 24
    • 79952168736 scopus 로고    scopus 로고
    • Diabetes and anti-platelet therapy in acute coronary syndrome
    • Ferreiro JL, Angiolillo DJ. Diabetes and anti-platelet therapy in acute coronary syndrome. Circulation 2011; 123: 798-813.
    • (2011) Circulation , vol.123 , pp. 798-813
    • Ferreiro, J.L.1    Angiolillo, D.J.2
  • 25
    • 33846656039 scopus 로고    scopus 로고
    • Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation
    • Geisler T, Anders N, Paterok M et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30: 372-4.
    • (2007) Diabetes Care , vol.30 , pp. 372-374
    • Geisler, T.1    Anders, N.2    Paterok, M.3
  • 26
    • 65349185008 scopus 로고    scopus 로고
    • Antiplatelet therapy in diabetes: Efficacy and limitations of current treatment strategies and future directions
    • Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009; 32: 531-40.
    • (2009) Diabetes Care , vol.32 , pp. 531-540
    • Angiolillo, D.J.1
  • 27
    • 45249099161 scopus 로고    scopus 로고
    • Platelet hyperactivity in type 2 diabetes: Role of antiplatelet agents
    • Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 2008; 5: 138-44.
    • (2008) Diab Vasc Dis Res , vol.5 , pp. 138-144
    • Natarajan, A.1    Zaman, A.G.2    Marshall, S.M.3
  • 28
    • 34047096264 scopus 로고    scopus 로고
    • Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1505-1516
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3
  • 29
    • 67749117943 scopus 로고    scopus 로고
    • Clopidogrel response variability: Current status and future directions
    • Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost 2009; 102: 7-14.
    • (2009) Thromb Haemost , vol.102 , pp. 7-14
    • Ferreiro, J.L.1    Angiolillo, D.J.2
  • 30
    • 0035899289 scopus 로고    scopus 로고
    • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    • Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
    • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
    • (2001) N Engl J Med , vol.345 , pp. 494-502
    • Yusuf, S.1    Zhao, F.2    Mehta, S.R.3    Chrolavicius, S.4    Tognoni, G.5    Fox, K.K.6
  • 31
    • 0030795973 scopus 로고    scopus 로고
    • Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
    • Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators
    • Mak KH, Moliterno DJ, Granger CB et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 171-9.
    • (1997) J Am Coll Cardiol , vol.30 , pp. 171-179
    • Mak, K.H.1    Moliterno, D.J.2    Granger, C.B.3
  • 32
    • 1242339648 scopus 로고    scopus 로고
    • Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes
    • Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2004; 25: 190-8.
    • (2004) Eur Heart J , vol.25 , pp. 190-198
    • Roffi, M.1    Topol, E.J.2
  • 33
    • 19944384222 scopus 로고    scopus 로고
    • Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)
    • CADILLAC investigators
    • Stuckey TD, Stone GW, Cox DA, et al. CADILLAC investigators. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol 2005; 95: 1-7.
    • (2005) Am J Cardiol , vol.95 , pp. 1-7
    • Stuckey, T.D.1    Stone, G.W.2    Cox, D.A.3
  • 35
    • 75149130955 scopus 로고    scopus 로고
    • Diagnosis and classification of diabetes mellitus
    • American Diabetes Association
    • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-S69.
    • (2010) Diabetes Care , vol.33
  • 36
    • 65349117529 scopus 로고    scopus 로고
    • Factors contributing to increased platelet reactivity in people with diabetes
    • Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care 2009; 32: 525-7.
    • (2009) Diabetes Care , vol.32 , pp. 525-527
    • Schneider, D.J.1
  • 38
    • 0037454139 scopus 로고    scopus 로고
    • Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus
    • Gresele P, Guglielmini G, De Angelis M et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-20.
    • (2003) J Am Coll Cardiol , vol.41 , pp. 1013-1020
    • Gresele, P.1    Guglielmini, G.2    de Angelis, M.3
  • 39
    • 0035077478 scopus 로고    scopus 로고
    • Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus
    • Yngen M, Ostenson CG, Li N, Hjemdahl P, Wallén NH. Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus. Blood Coagul Fibrinolysis 2001; 12: 109-16.
    • (2001) Blood Coagul Fibrinolysis , vol.12 , pp. 109-116
    • Yngen, M.1    Ostenson, C.G.2    Li, N.3    Hjemdahl, P.4    Wallén, N.H.5
  • 40
    • 49649090453 scopus 로고    scopus 로고
    • Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome
    • Undas A, Wiek I, Stêpien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 2008; 31: 1590-5.
    • (2008) Diabetes Care , vol.31 , pp. 1590-1595
    • Undas, A.1    Wiek, I.2    Stêpien, E.3    Zmudka, K.4    Tracz, W.5
  • 41
    • 33745017446 scopus 로고    scopus 로고
    • Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty
    • Yngen M, Norhammar A, Hjemdahl P, Wallén NH. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res 2006; 3: 52-6.
    • (2006) Diab Vasc Dis Res , vol.3 , pp. 52-56
    • Yngen, M.1    Norhammar, A.2    Hjemdahl, P.3    Wallén, N.H.4
  • 43
    • 0019857575 scopus 로고
    • Fibrinogen binding and ADPinduced aggregation in platelets from diabetic subjects
    • Leet H, Paton RC, Passa P, Caen JP. Fibrinogen binding and ADPinduced aggregation in platelets from diabetic subjects. Thromb Res 1981; 24: 143-50.
    • (1981) Thromb Res , vol.24 , pp. 143-150
    • Leet, H.1    Paton, R.C.2    Passa, P.3    Caen, J.P.4
  • 44
    • 79955155110 scopus 로고    scopus 로고
    • Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study (Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo)
    • Vivas D, García-Rubira JC, Bernardo E, et al. Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study (Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo). Heart 2011; 97: 803-9.
    • (2011) Heart , vol.97 , pp. 803-809
    • Vivas, D.1    García-Rubira, J.C.2    Bernardo, E.3
  • 45
    • 0030974812 scopus 로고    scopus 로고
    • Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group
    • Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997; 314: 1512-5.
    • (1997) BMJ , vol.314 , pp. 1512-1515
    • Malmberg, K.1
  • 46
    • 20244384563 scopus 로고    scopus 로고
    • Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity
    • DIGAMI 2 Investigators
    • Malmberg K, Rydén L, Wedel H, et al. DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-61.
    • (2005) Eur Heart J , vol.26 , pp. 650-661
    • Malmberg, K.1    Rydén, L.2    Wedel, H.3
  • 47
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 diabetes
    • Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
    • (2008) N Engl J Med , vol.358 , pp. 2545-2559
    • Gerstein, H.C.1    Miller, M.E.2    Byington, R.P.3
  • 48
    • 63249128249 scopus 로고    scopus 로고
    • Intensive versus conventional glucose control in critically ill patients
    • NICE-SUGAR Study Investigators
    • Finfer S, Chittock DR, Su SY, et al. NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-97.
    • (2009) N Engl J Med , vol.360 , pp. 1283-1297
    • Finfer, S.1    Chittock, D.R.2    Su, S.Y.3
  • 49
    • 0026437818 scopus 로고
    • Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins
    • Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost 1992; 68: 577-82.
    • (1992) Thromb Haemost , vol.68 , pp. 577-582
    • Winocour, P.D.1    Watala, C.2    Perry, D.W.3    Kinlough-Rathbone, R.L.4
  • 50
    • 0031659657 scopus 로고    scopus 로고
    • Membrane lipid fluidity of blood platelets: A common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood
    • Watala C, Golański J, Boncler MA, Pietrucha T, Gwoździński K. Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. Platelets 1998; 9: 315-27.
    • (1998) Platelets , vol.9 , pp. 315-327
    • Watala, C.1    Golański, J.2    Boncler, M.A.3    Pietrucha, T.4    Gwoździński, K.5
  • 51
    • 0031048334 scopus 로고    scopus 로고
    • Advanced glycation end products, oxidant stress and vascular lesions
    • Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997; 27: 97-108.
    • (1997) Eur J Clin Invest , vol.27 , pp. 97-108
    • Chappey, O.1    Dosquet, C.2    Wautier, M.P.3    Wautier, J.L.4
  • 52
    • 0242488090 scopus 로고    scopus 로고
    • Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus
    • Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 2003; 92: 1362-5.
    • (2003) Am J Cardiol , vol.92 , pp. 1362-1365
    • Keating, F.K.1    Sobel, B.E.2    Schneider, D.J.3
  • 53
    • 0035131476 scopus 로고    scopus 로고
    • Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro
    • Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44: 188-95.
    • (2001) Diabetologia , vol.44 , pp. 188-195
    • Assert, R.1    Scherk, G.2    Bumbure, A.3    Pirags, V.4    Schatz, H.5    Pfeiffer, A.F.6
  • 54
    • 0027981889 scopus 로고
    • Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia
    • Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994; 43: 1122-9.
    • (1994) Diabetes , vol.43 , pp. 1122-1129
    • Xia, P.1    Inoguchi, T.2    Kern, T.S.3    Engerman, R.L.4    Oates, P.J.5    King, G.L.6
  • 55
    • 0036096133 scopus 로고    scopus 로고
    • Glycated low density lipoproteins modify platelet properties: A compositional and functional study
    • Ferretti G, Rabini RA, Bacchetti T et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 2002; 87: 2180-4.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 2180-2184
    • Ferretti, G.1    Rabini, R.A.2    Bacchetti, T.3
  • 56
    • 0032485927 scopus 로고    scopus 로고
    • Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo
    • Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998; 97: 1695-701.
    • (1998) Circulation , vol.97 , pp. 1695-1701
    • Williams, S.B.1    Goldfine, A.B.2    Timimi, F.K.3
  • 57
    • 0034643340 scopus 로고    scopus 로고
    • Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
    • Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
    • (2000) Nature , vol.404 , pp. 787-790
    • Nishikawa, T.1    Edelstein, D.2    Du, X.L.3
  • 59
    • 34250768930 scopus 로고    scopus 로고
    • Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation
    • Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007; 7: 223-7.
    • (2007) Curr Diab Rep , vol.7 , pp. 223-227
    • Boden, G.1    Rao, A.K.2
  • 60
    • 0027254691 scopus 로고
    • Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus
    • Takada Y, Urano T, Watanabe I, Taminato A, Yoshimi T, Takada A. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1993; 71: 405-15.
    • (1993) Thromb Res , vol.71 , pp. 405-415
    • Takada, Y.1    Urano, T.2    Watanabe, I.3    Taminato, A.4    Yoshimi, T.5    Takada, A.6
  • 61
    • 65349085512 scopus 로고    scopus 로고
    • Insulin, insulin resistance, and platelet signaling in diabetes
    • Randriamboavonjy V, Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. Diabetes Care 2009; 32: 528-30.
    • (2009) Diabetes Care , vol.32 , pp. 528-530
    • Randriamboavonjy, V.1    Fleming, I.2
  • 62
    • 0032561146 scopus 로고    scopus 로고
    • Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gi alpha protein
    • Kahn NN. Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gi alpha protein. Life Sci 1998; 63: 2031-8.
    • (1998) Life Sci , vol.63 , pp. 2031-2038
    • Kahn, N.N.1
  • 63
    • 0028816017 scopus 로고
    • Insulin-induced release of plasminogen activator from human blood platelets
    • Kahn NN, Bauman WA, Sinha AK. Insulin-induced release of plasminogen activator from human blood platelets. Am J Physiol 1995; 268: H117-24.
    • (1995) Am J Physiol , vol.268
    • Kahn, N.N.1    Bauman, W.A.2    Sinha, A.K.3
  • 64
  • 65
    • 77449091982 scopus 로고    scopus 로고
    • Insulin/IGF-1 hybrid receptor expression on human platelets: Consequences for the effect of insulin on platelet function
    • Hunter RW, Hers I. Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. J Thromb Haemost 2009; 7: 2123-30.
    • (2009) J Thromb Haemost , vol.7 , pp. 2123-2130
    • Hunter, R.W.1    Hers, I.2
  • 66
    • 39649102180 scopus 로고    scopus 로고
    • Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway
    • Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway. Blood 2007; 110: 4243-52.
    • (2007) Blood , vol.110 , pp. 4243-4252
    • Hers, I.1
  • 67
    • 0036144715 scopus 로고    scopus 로고
    • Inhibition of platelet-collagen interaction: An in vivo action of insulin abolished by insulin resistance in obesity
    • Westerbacka J, Yki-Järvinen H, Turpeinen A et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002; 22: 167-72.
    • (2002) Arterioscler Thromb Vasc Biol , vol.22 , pp. 167-172
    • Westerbacka, J.1    Yki-Järvinen, H.2    Turpeinen, A.3
  • 68
    • 79959513241 scopus 로고    scopus 로고
    • Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease
    • Angiolillo DJ, Bernardo E, Zanoni M, Vivas D, Capranzano P, Malerba G, et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2011; 58: 30-9.
    • (2011) J Am Coll Cardiol , vol.58 , pp. 30-39
    • Angiolillo, D.J.1    Bernardo, E.2    Zanoni, M.3    Vivas, D.4    Capranzano, P.5    Malerba, G.6
  • 69
    • 0029743495 scopus 로고    scopus 로고
    • Effects of insulin on calcium metabolism and platelet aggregation
    • Ishida M, Ishida T, Ono N et al. Effects of insulin on calcium metabolism and platelet aggregation. Hypertension 1996; 28: 209-12.
    • (1996) Hypertension , vol.28 , pp. 209-212
    • Ishida, M.1    Ishida, T.2    Ono, N.3
  • 70
    • 0030813544 scopus 로고    scopus 로고
    • Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart
    • Algenstaedt P, Antonetti DA, Yaffe MB, Kahn CR. Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart. J Biol Chem 1997; 272: 23696-702.
    • (1997) J Biol Chem , vol.272 , pp. 23696-23702
    • Algenstaedt, P.1    Antonetti, D.A.2    Yaffe, M.B.3    Kahn, C.R.4
  • 71
    • 0942276398 scopus 로고    scopus 로고
    • IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi
    • Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 2004; 279: 3254-64.
    • (2004) J Biol Chem , vol.279 , pp. 3254-3264
    • Ferreira, I.A.1    Eybrechts, K.L.2    Mocking, A.I.3    Kroner, C.4    Akkerman, J.W.5
  • 73
    • 0031985026 scopus 로고    scopus 로고
    • Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM
    • Anfossi G, Mularoni EM, Burzacca S et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998; 21: 121-6.
    • (1998) Diabetes Care , vol.21 , pp. 121-126
    • Anfossi, G.1    Mularoni, E.M.2    Burzacca, S.3
  • 74
    • 77950189188 scopus 로고    scopus 로고
    • In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin
    • Russo I, Traversa M, Bonomo K et al. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity (Silver Spring) 2010; 18: 788-97.
    • (2010) Obesity (Silver Spring) , vol.18 , pp. 788-797
    • Russo, I.1    Traversa, M.2    Bonomo, K.3
  • 75
    • 37349104971 scopus 로고    scopus 로고
    • Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone
    • Randriamboavonjy V, Pistrosch F, Bölck B et al. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation 2008; 117: 52-60.
    • (2008) Circulation , vol.117 , pp. 52-60
    • Randriamboavonjy, V.1    Pistrosch, F.2    Bölck, B.3
  • 76
    • 4544235535 scopus 로고    scopus 로고
    • Peroxisome proliferatoractivated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease
    • Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferatoractivated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004; 147: e25.
    • (2004) Am Heart J , vol.147
    • Sidhu, J.S.1    Cowan, D.2    Tooze, J.A.3    Kaski, J.C.4
  • 77
    • 41649084422 scopus 로고    scopus 로고
    • Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial
    • PERISCOPE Investigators
    • Nissen SE, Nicholls SJ, Wolski K, et al. PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-73.
    • (2008) JAMA , vol.299 , pp. 1561-1573
    • Nissen, S.E.1    Nicholls, S.J.2    Wolski, K.3
  • 78
    • 10744231601 scopus 로고    scopus 로고
    • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes
    • SYMPHONY and 2nd SYMPHONY Investigators
    • McGuire DK, Newby LK, Bhapkar MV, et al. SYMPHONY and 2nd SYMPHONY Investigators. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004; 147: 246-52.
    • (2004) Am Heart J , vol.147 , pp. 246-252
    • McGuire, D.K.1    Newby, L.K.2    Bhapkar, M.V.3
  • 79
    • 77950474638 scopus 로고    scopus 로고
    • Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: The assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial
    • APPROACH Study Group
    • Gerstein HC, Ratner RE, Cannon CP, et al. APPROACH Study Group. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010; 121: 1176-87.
    • (2010) Circulation , vol.121 , pp. 1176-1187
    • Gerstein, H.C.1    Ratner, R.E.2    Cannon, C.P.3
  • 80
    • 79751504243 scopus 로고    scopus 로고
    • Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients
    • Harmsze AM, Van Werkum JW, Moral F, et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011; 22: 98-102.
    • (2011) Platelets , vol.22 , pp. 98-102
    • Harmsze, A.M.1    van Werkum, J.W.2    Moral, F.3
  • 81
    • 44949092445 scopus 로고    scopus 로고
    • Determinants of mean platelet volume (MPV) in an elderly population: Relevance of body fat, blood glucose and ischaemic electrocardiographic changes
    • Muscari A, De Pascalis S, Cenni A et al. Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost 2008; 99: 1079-84.
    • (2008) Thromb Haemost , vol.99 , pp. 1079-1084
    • Muscari, A.1    de Pascalis, S.2    Cenni, A.3
  • 82
    • 70349260634 scopus 로고    scopus 로고
    • The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases
    • Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 2009; 63: 1509-15.
    • (2009) Int J Clin Pract , vol.63 , pp. 1509-1515
    • Vizioli, L.1    Muscari, S.2    Muscari, A.3
  • 83
    • 79960080757 scopus 로고    scopus 로고
    • Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome
    • Taglieri N, Saia F, Rapezzi C, et al. Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. Thromb Haemost. 2011; 106: 132-40.
    • (2011) Thromb Haemost , vol.106 , pp. 132-140
    • Taglieri, N.1    Saia, F.2    Rapezzi, C.3
  • 84
    • 33947138202 scopus 로고    scopus 로고
    • Platelet aggregation in obese and diabetic subjects: Association with leptin level
    • Sugiyama C, Ishizawa M, Kajita K et al. Platelet aggregation in obese and diabetic subjects: association with leptin level. Platelets 2007; 18: 128-34.
    • (2007) Platelets , vol.18 , pp. 128-134
    • Sugiyama, C.1    Ishizawa, M.2    Kajita, K.3
  • 85
    • 0026089056 scopus 로고
    • Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium
    • Scherrer U, Nussberger J, Torriani S et al. Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium. Circulation 1991; 83: 552-8.
    • (1991) Circulation , vol.83 , pp. 552-558
    • Scherrer, U.1    Nussberger, J.2    Torriani, S.3
  • 87
    • 65949112701 scopus 로고    scopus 로고
    • Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: A BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy
    • Pro-Thrombosis Ancillary Study Group
    • Schneider DJ, Hardison RM, Lopes N, Sobel BE, Brooks MM; Pro-Thrombosis Ancillary Study Group. Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy. Diabetes Care. 2009; 32: 944-9.
    • (2009) Diabetes Care , vol.32 , pp. 944-949
    • Schneider, D.J.1    Hardison, R.M.2    Lopes, N.3    Sobel, B.E.4    Brooks, M.M.5
  • 88
    • 33750842744 scopus 로고    scopus 로고
    • Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity
    • Murakami T, Horigome H, Tanaka K, et al. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res. 2007; 119: 45-53.
    • (2007) Thromb Res , vol.119 , pp. 45-53
    • Murakami, T.1    Horigome, H.2    Tanaka, K.3
  • 89
    • 11144355993 scopus 로고    scopus 로고
    • Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loading-dose be weight adjusted?
    • Angiolillo DJ, Fernández-Ortiz A, Bernardo E et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004; 16: 169-74.
    • (2004) J Invasive Cardiol , vol.16 , pp. 169-174
    • Angiolillo, D.J.1    Fernández-Ortiz, A.2    Bernardo, E.3
  • 90
    • 34447274446 scopus 로고    scopus 로고
    • Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention
    • Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100: 203-5.
    • (2007) Am J Cardiol , vol.100 , pp. 203-205
    • Sibbing, D.1    von Beckerath, O.2    Schömig, A.3    Kastrati, A.4    von Beckerath, N.5
  • 91
    • 77952591958 scopus 로고    scopus 로고
    • Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
    • Hochholzer W, Trenk D, Fromm MF et al Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-34.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2427-2434
    • Hochholzer, W.1    Trenk, D.2    Fromm, M.F.3
  • 92
    • 0033812287 scopus 로고    scopus 로고
    • Activated platelets in patients with severe hypertriglyceridemia: Effects of triglyceride-lowering therapy
    • de Man FH, Nieuwland R, van der Laarse A et al. Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy. Atherosclerosis 2000; 152: 407-14.
    • (2000) Atherosclerosis , vol.152 , pp. 407-414
    • de Man, F.H.1    Nieuwland, R.2    van der Laarse, A.3
  • 93
    • 33746633023 scopus 로고    scopus 로고
    • Effects of VLDL and remnant particles on platelets
    • Olufadi R, Byrne CD. Effects of VLDL and remnant particles on platelets. Pathophysiol Haemost Thromb 2006; 35: 281-91.
    • (2006) Pathophysiol Haemost Thromb , vol.35 , pp. 281-291
    • Olufadi, R.1    Byrne, C.D.2
  • 94
    • 0034234402 scopus 로고    scopus 로고
    • Platelet function in patients with familial hypertriglyceridemia: Evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles
    • Pedreño J, Hurt-Camejo E, Wiklund O, Badimón L, Masana L. Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles. Metabolism 2000; 49: 942-9.
    • (2000) Metabolism , vol.49 , pp. 942-949
    • Pedreño, J.1    Hurt-Camejo, E.2    Wiklund, O.3    Badimón, L.4    Masana, L.5
  • 95
    • 0026316004 scopus 로고
    • Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity
    • Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 1991; 68: 1425-30.
    • (1991) Am J Cardiol , vol.68 , pp. 1425-1430
    • Kuhn, F.E.1    Mohler, E.R.2    Satler, L.F.3    Reagan, K.4    Lu, D.Y.5    Rackley, C.E.6
  • 96
    • 0037177140 scopus 로고    scopus 로고
    • High-density lipoprotein restores endothelial function in hypercholesterolemic men
    • Spieker LE, Sudano I, Hürlimann D et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-402.
    • (2002) Circulation , vol.105 , pp. 1399-1402
    • Spieker, L.E.1    Sudano, I.2    Hürlimann, D.3
  • 97
    • 73449107142 scopus 로고    scopus 로고
    • Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux
    • Calkin AC, Drew BG, Ono A et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009; 120: 2095-104.
    • (2009) Circulation , vol.120 , pp. 2095-2104
    • Calkin, A.C.1    Drew, B.G.2    Ono, A.3
  • 98
    • 2642522886 scopus 로고    scopus 로고
    • Soluble CD40 ligand, soluble P- selectin, interleukin-6, and tissue factor in diabetes mellitus: Relationships to cardiovascular disease and risk factor intervention
    • Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P- selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004; 109: 2524-8.
    • (2004) Circulation , vol.109 , pp. 2524-2528
    • Lim, H.S.1    Blann, A.D.2    Lip, G.Y.3
  • 99
    • 0037392234 scopus 로고    scopus 로고
    • Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus
    • Calverley DC, Hacker MR, Loda KA et al. Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol 2003; 121: 139-42.
    • (2003) Br J Haematol , vol.121 , pp. 139-142
    • Calverley, D.C.1    Hacker, M.R.2    Loda, K.A.3
  • 100
    • 39749117423 scopus 로고    scopus 로고
    • Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis
    • Belostocki K, Pricop L, Redecha PB et al. Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 384-8.
    • (2008) Arthritis Rheum , vol.58 , pp. 384-388
    • Belostocki, K.1    Pricop, L.2    Redecha, P.B.3
  • 101
    • 0035008904 scopus 로고    scopus 로고
    • Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus
    • Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001; 280: H1480-9.
    • (2001) Am J Physiol Heart Circ Physiol , vol.280
    • Li, Y.1    Woo, V.2    Bose, R.3
  • 103
    • 0033069782 scopus 로고    scopus 로고
    • Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production
    • Schaeffer G, Wascher TC, Kostner GM, Graier WF. Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia. 1999; 42: 167-76.
    • (1999) Diabetologia , vol.42 , pp. 167-176
    • Schaeffer, G.1    Wascher, T.C.2    Kostner, G.M.3    Graier, W.F.4
  • 104
    • 0025868650 scopus 로고
    • Increased intracellular calcium mobilization in platelets from patients with type 2 (noninsulin-dependent) diabetes mellitus
    • Ishii H, Umeda F, Hashimoto T, Nawata H. Increased intracellular calcium mobilization in platelets from patients with type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia. 1991; 34: 332-6.
    • (1991) Diabetologia , vol.34 , pp. 332-336
    • Ishii, H.1    Umeda, F.2    Hashimoto, T.3    Nawata, H.4
  • 106
    • 0034991329 scopus 로고    scopus 로고
    • Platelet antioxidant enzymes in insulin-dependent diabetes mellitus
    • Seghieri G, Di Simplicio P, Anichini R et al. Platelet antioxidant enzymes in insulin-dependent diabetes mellitus. Clin Chim Acta 2001; 309: 19-23.
    • (2001) Clin Chim Acta , vol.309 , pp. 19-23
    • Seghieri, G.1    Di Simplicio, P.2    Anichini, R.3
  • 107
    • 33747803057 scopus 로고    scopus 로고
    • Endogenously generated reactive oxygen species reduce PMCA activity in platelets from patients with non-insulin-dependent diabetes mellitus
    • Jardín I, Redondo PC, Salido GM, Pariente JA, Rosado JA. Endogenously generated reactive oxygen species reduce PMCA activity in platelets from patients with non-insulin-dependent diabetes mellitus. Platelets 2006; 17: 283-8.
    • (2006) Platelets , vol.17 , pp. 283-288
    • Jardín, I.1    Redondo, P.C.2    Salido, G.M.3    Pariente, J.A.4    Rosado, J.A.5
  • 109
    • 0034643340 scopus 로고    scopus 로고
    • Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
    • Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
    • (2000) Nature , vol.404 , pp. 787-790
    • Nishikawa, T.1    Edelstein, D.2    Du, X.L.3
  • 110
    • 0344286498 scopus 로고    scopus 로고
    • Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
    • Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97.
    • (1999) Circ Res , vol.84 , pp. 489-497
    • Schmidt, A.M.1    Yan, S.D.2    Wautier, J.L.3    Stern, D.4
  • 111
    • 0037107272 scopus 로고    scopus 로고
    • Enhancing effect of advanced glycation end products on serotonininduced platelet aggregation in patients with diabetes mellitus
    • Hasegawa Y, Suehiro A, Higasa S, Namba M, Kakishita E. Enhancing effect of advanced glycation end products on serotonininduced platelet aggregation in patients with diabetes mellitus. Thromb Res 2002; 107: 319-23.
    • (2002) Thromb Res , vol.107 , pp. 319-323
    • Hasegawa, Y.1    Suehiro, A.2    Higasa, S.3    Namba, M.4    Kakishita, E.5
  • 112
    • 43249107774 scopus 로고    scopus 로고
    • Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis
    • Schäfer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008; 6: 52-60.
    • (2008) Curr Vasc Pharmacol , vol.6 , pp. 52-60
    • Schäfer, A.1    Bauersachs, J.2
  • 113
    • 0029085504 scopus 로고
    • Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria
    • Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol. 1995; 15: 1114-20.
    • (1995) Arterioscler Thromb Vasc Biol , vol.15 , pp. 1114-1120
    • Kario, K.1    Matsuo, T.2    Kobayashi, H.3    Matsuo, M.4    Sakata, T.5    Miyata, T.6
  • 114
    • 14044275187 scopus 로고    scopus 로고
    • P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes
    • Matsuno H, Tokuda H, Ishisaki A, Zhou Y, Kitajima Y, Kozawa O. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J Clin Endocrinol Metab 2005; 90: 920-7.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 920-927
    • Matsuno, H.1    Tokuda, H.2    Ishisaki, A.3    Zhou, Y.4    Kitajima, Y.5    Kozawa, O.6
  • 115
    • 79952165871 scopus 로고    scopus 로고
    • Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease
    • Ueno M, Ferreiro JL, Tomasello SD, et al. Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. Thromb Haemost 2011; 105: 730-2.
    • (2011) Thromb Haemost , vol.105 , pp. 730-732
    • Ueno, M.1    Ferreiro, J.L.2    Tomasello, S.D.3
  • 116
  • 117
    • 56849130022 scopus 로고    scopus 로고
    • Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
    • Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968-77.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 1968-1977
    • Erlinge, D.1    Varenhorst, C.2    Braun, O.O.3
  • 118
    • 84870964940 scopus 로고    scopus 로고
    • Serum cotinine levels are associated with increased clopidogrel-induced antiplatelet effects in patients with diabetes mellitus and coronary artery disease
    • Ueno M, Ferreiro JL, Dharmashankar K, et al. Serum cotinine levels are associated with increased clopidogrel-induced antiplatelet effects in patients with diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2011; 57: E1919 [abstract]
    • (2011) J Am Coll Cardiol , vol.57
    • Ueno, M.1    Ferreiro, J.L.2    Dharmashankar, K.3
  • 119
    • 0025214340 scopus 로고
    • Evidence for abnormal platelet glycoprotein expression in diabetes mellitus
    • Tschoepe D, Roesen P, Kaufmann L et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 1990; 20: 166-70.
    • (1990) Eur J Clin Invest , vol.20 , pp. 166-170
    • Tschoepe, D.1    Roesen, P.2    Kaufmann, L.3
  • 120
    • 0022970057 scopus 로고
    • Trial of repeated low-dose aspirin in diabetic angiopathy
    • DiMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-91.
    • (1986) Blood , vol.68 , pp. 886-891
    • Diminno, G.1    Silver, M.J.2    Cerbone, A.M.3    Murphy, S.4
  • 121
    • 34247574729 scopus 로고    scopus 로고
    • Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin
    • Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost. 2007; 5: 490-6.
    • (2007) J Thromb Haemost , vol.5 , pp. 490-496
    • Guthikonda, S.1    Lev, E.I.2    Patel, R.3
  • 122
    • 49349102948 scopus 로고    scopus 로고
    • Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease
    • Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008; 52: 743-9.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 743-749
    • Guthikonda, S.1    Alviar, C.L.2    Vaduganathan, M.3
  • 123
    • 78650952436 scopus 로고    scopus 로고
    • Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease
    • Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9: 185-91.
    • (2011) J Thromb Haemost , vol.9 , pp. 185-191
    • Grove, E.L.1    Hvas, A.M.2    Mortensen, S.B.3    Larsen, S.B.4    Kristensen, S.D.5
  • 124
    • 0026341861 scopus 로고
    • Large platelets circulate in an activated state in diabetes mellitus
    • Tschoepe D, Roesen P, Esser J et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433-8.
    • (1991) Semin Thromb Hemost , vol.17 , pp. 433-438
    • Tschoepe, D.1    Roesen, P.2    Esser, J.3
  • 126
    • 37349031812 scopus 로고    scopus 로고
    • 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina
    • American College of Cardiology; American Heart Association; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group
    • Fraker TD Jr, Fihn SD, Gibbons RJ, et al. American College of Cardiology; American Heart Association; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 2007; 116: 2762-72.
    • (2007) Circulation , vol.116 , pp. 2762-2772
    • Fraker Jr., T.D.1    Fihn, S.D.2    Gibbons, R.J.3
  • 127
    • 79955760903 scopus 로고    scopus 로고
    • ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-STElevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    • Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-STElevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: e426-579.
    • (2011) Circulation , vol.123 , pp. 426-579
    • Anderson, J.L.1    Adams, C.D.2    Antman, E.M.3
  • 128
    • 73449142798 scopus 로고    scopus 로고
    • 2009 focused updates: ACC/AHA guidelines for the management of patients with STelevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice
    • Guidelines
    • Kushner FG, Hand M, Smith SC Jr et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with STelevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-306.
    • (2009) Circulation , vol.120 , pp. 2271-2306
    • Kushner, F.G.1    Hand, M.2    Smith Jr., S.C.3
  • 130
    • 0023845856 scopus 로고
    • Randomised trial of prophylactic daily aspirin in British male doctors
    • Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313-6.
    • (1988) Br Med J (Clin Res Ed) , vol.296 , pp. 313-316
    • Peto, R.1    Gray, R.2    Collins, R.3
  • 131
    • 0024406369 scopus 로고
    • Final report on the aspirin component of the ongoing Physicians' Health Study
    • Steering Committee of the Physicians' Health Study Research Group
    • Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
    • (1989) N Engl J Med , vol.321 , pp. 129-135
  • 132
    • 0032513878 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
    • HOT Study Group
    • Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
    • (1998) Lancet , vol.351 , pp. 1755-1762
    • Hansson, L.1    Zanchetti, A.2    Carruthers, S.G.3
  • 133
    • 0032562005 scopus 로고    scopus 로고
    • The Medical Research Council's General Practice Research Framework
    • Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
    • Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233-41.
    • (1998) Lancet , vol.351 , pp. 233-241
  • 134
    • 0345411332 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial
    • Sacco M, Pellegrini F, Roncaglioni MC et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-72.
    • (2003) Diabetes Care , vol.26 , pp. 3264-3272
    • Sacco, M.1    Pellegrini, F.2    Roncaglioni, M.C.3
  • 135
    • 15744378579 scopus 로고    scopus 로고
    • A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women
    • Ridker PM, Cook NR, Lee IM et al. A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
    • (2005) N Engl J Med , vol.352 , pp. 1293-1304
    • Ridker, P.M.1    Cook, N.R.2    Lee, I.M.3
  • 136
    • 0026775578 scopus 로고
    • Early Treatment Diabetic Retinopathy Study report 14
    • ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus
    • ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992; 268: 1292-300.
    • (1992) JAMA , vol.268 , pp. 1292-1300
  • 137
    • 55949127696 scopus 로고    scopus 로고
    • The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
    • Belch J, MacCuish A, Campbell I et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
    • (2008) BMJ , vol.337
    • Belch, J.1    Maccuish, A.2    Campbell, I.3
  • 138
    • 56149113603 scopus 로고    scopus 로고
    • Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial
    • Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators
    • Ogawa H, Nakayama M, Morimoto T, et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-41.
    • (2008) JAMA , vol.300 , pp. 2134-2141
    • Ogawa, H.1    Nakayama, M.2    Morimoto, T.3
  • 139
    • 65849268320 scopus 로고    scopus 로고
    • Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials
    • Antithrombotic Trialists' (ATT) Collaboration
    • Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60.
    • (2009) Lancet , vol.373 , pp. 1849-1860
    • Baigent, C.1    Blackwell, L.2    Collins, R.3
  • 140
    • 71749105108 scopus 로고    scopus 로고
    • Aspirin for primary prevention of cardiovascular events in people with diabetes: Metaanalysis of randomised controlled trials
    • De Berardis G, Sacco M, Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: metaanalysis of randomised controlled trials. BMJ 2009; 339: b4531.
    • (2009) BMJ , vol.339
    • de Berardis, G.1    Sacco, M.2    Strippoli, G.F.3
  • 141
    • 72249095825 scopus 로고    scopus 로고
    • Aspirin for the primary prevention of cardiovascular events: A systematic review and meta-analysis comparing patients with and without diabetes
    • Calvin AD, Aggarwal NR, Murad MH et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009; 32: 2300-6.
    • (2009) Diabetes Care , vol.32 , pp. 2300-2306
    • Calvin, A.D.1    Aggarwal, N.R.2    Murad, M.H.3
  • 142
    • 77953320338 scopus 로고    scopus 로고
    • Aspirin for primary prevention of cardiovascular events in people with diabetes
    • Pignone M, Alberts MJ, Colwell JA et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55: 2878-86.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2878-2886
    • Pignone, M.1    Alberts, M.J.2    Colwell, J.A.3
  • 143
    • 33846414720 scopus 로고    scopus 로고
    • Guidelines on diabetes, prediabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    • Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
    • (2007) Eur Heart J , vol.28 , pp. 88-136
    • Rydén, L.1    Standl, E.2    Bartnik, M.3
  • 144
    • 33846025092 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association
    • Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162-72.
    • (2007) Diabetes Care , vol.30 , pp. 162-172
    • Buse, J.B.1    Ginsberg, H.N.2    Bakris, G.L.3
  • 145
    • 1042268057 scopus 로고    scopus 로고
    • Aspirin therapy in diabetes
    • American Diabetes Association
    • Colwell JA; American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004; 27 Suppl 1: S72-3.
    • (2004) Diabetes Care , vol.27 , Issue.1 SUPPL. 1
    • Colwell, J.A.1
  • 146
    • 0020528647 scopus 로고
    • Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study
    • Lewis HD Jr, Davis JW, Archibald DG et al Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.
    • (1983) N Engl J Med , vol.309 , pp. 396-403
    • Lewis Jr., H.D.1    Davis, J.W.2    Archibald, D.G.3
  • 147
    • 0023754429 scopus 로고
    • Aspirin, heparin, or both to treat acute unstable angina
    • Théroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
    • (1988) N Engl J Med , vol.319 , pp. 1105-1111
    • Théroux, P.1    Ouimet, H.2    McCans, J.3
  • 148
    • 0025090942 scopus 로고
    • Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
    • The RISC Group
    • The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
    • (1990) Lancet , vol.336 , pp. 827-830
  • 149
    • 0023805341 scopus 로고
    • Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
    • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
    • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
    • (1988) Lancet , vol.2 , pp. 349-360
  • 150
    • 0026541425 scopus 로고
    • Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: A meta-analysis
    • Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992; 19: 671-7.
    • (1992) J Am Coll Cardiol , vol.19 , pp. 671-677
    • Roux, S.1    Christeller, S.2    Lüdin, E.3
  • 151
    • 0028120906 scopus 로고
    • Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
    • Antiplatelet Trialists' Collaboration
    • Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308: 81-106.
    • (1994) BMJ , vol.308 , pp. 81-106
  • 152
    • 0037065502 scopus 로고    scopus 로고
    • Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
    • Antithrombotic Trialists' Collaboration
    • Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86.
    • (2002) BMJ , vol.324 , pp. 71-86
  • 153
    • 58249142825 scopus 로고    scopus 로고
    • Variability in responsiveness to oral antiplatelet therapy
    • Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol. 2009; 103(3 Suppl): 27A-34A.
    • (2009) Am J Cardiol , vol.103 , Issue.3 SUPPL.
    • Angiolillo, D.J.1
  • 154
    • 24944474901 scopus 로고    scopus 로고
    • Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: Position paper of the Working Group on Aspirin Resistance
    • Michelson AD, Cattaneo M, Eikelboom JW, et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005; 3: 1309-11.
    • (2005) J Thromb Haemost , vol.3 , pp. 1309-1311
    • Michelson, A.D.1    Cattaneo, M.2    Eikelboom, J.W.3
  • 155
    • 34447503098 scopus 로고    scopus 로고
    • Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis
    • Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-9.
    • (2007) Arch Intern Med , vol.167 , pp. 1593-1599
    • Snoep, J.D.1    Hovens, M.M.2    Eikenboom, J.C.3    van der Bom, J.G.4    Huisman, M.V.5
  • 156
    • 38949119325 scopus 로고    scopus 로고
    • Aspirin resistance and risk of cardiovascular morbidity: Systematic review and meta-analysis
    • Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-8.
    • (2008) BMJ , vol.336 , pp. 195-198
    • Krasopoulos, G.1    Brister, S.J.2    Beattie, W.S.3    Buchanan, M.R.4
  • 157
    • 77953160638 scopus 로고    scopus 로고
    • A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease
    • Grove EL, Hvas AM, Johnsen HL et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-53.
    • (2010) Thromb Haemost , vol.103 , pp. 1245-1253
    • Grove, E.L.1    Hvas, A.M.2    Johnsen, H.L.3
  • 158
    • 34347340649 scopus 로고    scopus 로고
    • Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study
    • Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-64.
    • (2007) Circulation , vol.115 , pp. 3156-3164
    • Gurbel, P.A.1    Bliden, K.P.2    Dichiara, J.3
  • 159
    • 33747088257 scopus 로고    scopus 로고
    • Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2- independent pathway: A 700-patient study of aspirin resistance
    • Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2- independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-96.
    • (2006) Circulation , vol.113 , pp. 2888-2896
    • Frelinger III, A.L.1    Furman, M.I.2    Linden, M.D.3
  • 160
    • 77957113521 scopus 로고    scopus 로고
    • Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus
    • Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010; 126: e318-22.
    • (2010) Thromb Res , vol.126 , pp. 318-322
    • Mortensen, S.B.1    Larsen, S.B.2    Grove, E.L.3    Kristensen, S.D.4    Hvas, A.M.5
  • 161
    • 0025282786 scopus 로고
    • Thromboxane biosynthesis and platelet function in type II diabetes mellitus
    • Davì G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-74.
    • (1990) N Engl J Med , vol.322 , pp. 1769-1774
    • Davì, G.1    Catalano, I.2    Averna, M.3
  • 162
    • 2042504400 scopus 로고    scopus 로고
    • Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control
    • Watala C, Golanski J, Pluta J et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004; 113: 101-13.
    • (2004) Thromb Res , vol.113 , pp. 101-113
    • Watala, C.1    Golanski, J.2    Pluta, J.3
  • 163
    • 33747168513 scopus 로고    scopus 로고
    • Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers
    • Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153-8.
    • (2006) Stroke , vol.37 , pp. 2153-2158
    • Cox, D.1    Maree, A.O.2    Dooley, M.3    Conroy, R.4    Byrne, M.F.5    Fitzgerald, D.J.6
  • 164
    • 28444484957 scopus 로고    scopus 로고
    • Cyclooxygenase-1 haplotype modulates platelet response to aspirin
    • Maree AO, Curtin RJ, Chubb A et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-5.
    • (2005) J Thromb Haemost , vol.3 , pp. 2340-2345
    • Maree, A.O.1    Curtin, R.J.2    Chubb, A.3
  • 165
    • 0035924765 scopus 로고    scopus 로고
    • Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
    • Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
    • (2001) N Engl J Med , vol.345 , pp. 1809-1817
    • Catella-Lawson, F.1    Reilly, M.P.2    Kapoor, S.C.3
  • 167
    • 0035181313 scopus 로고    scopus 로고
    • Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood
    • Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001; 12: 443-7.
    • (2001) Platelets , vol.12 , pp. 443-447
    • Storey, R.F.1    Newby, L.J.2    Heptinstall, S.3
  • 168
    • 0034911702 scopus 로고    scopus 로고
    • ADP receptors of platelets and their inhibition
    • Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-32.
    • (2001) Thromb Haemost , vol.86 , pp. 222-232
    • Gachet, C.1
  • 169
    • 0035760304 scopus 로고    scopus 로고
    • Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow
    • Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001; 98: 3340-5.
    • (2001) Blood , vol.98 , pp. 3340-3345
    • Turner, N.A.1    Moake, J.L.2    McIntire, L.V.3
  • 170
    • 0034622539 scopus 로고    scopus 로고
    • Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)
    • CLASSICS Investigators
    • Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-9.
    • (2000) Circulation , vol.102 , pp. 624-629
    • Bertrand, M.E.1    Rupprecht, H.J.2    Urban, P.3    Gershlick, A.H.4
  • 171
    • 0034691260 scopus 로고    scopus 로고
    • Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
    • Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101: 2823-8.
    • (2000) Circulation , vol.101 , pp. 2823-2828
    • Cadroy, Y.1    Bossavy, J.P.2    Thalamas, C.3    Sagnard, L.4    Sakariassen, K.5    Boneu, B.6
  • 172
    • 0030590746 scopus 로고    scopus 로고
    • A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
    • CAPRIE Steering Committee
    • CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
    • (1996) Lancet , vol.348 , pp. 1329-1339
  • 174
    • 0035908781 scopus 로고    scopus 로고
    • Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
    • Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
    • Mehta SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
    • (2001) Lancet , vol.358 , pp. 527-533
    • Mehta, S.R.1    Yusuf, S.2    Peters, R.J.3
  • 175
    • 0037145863 scopus 로고    scopus 로고
    • Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
    • CREDO Investigators
    • Steinhubl SR, Berger PB, Mann JT 3rd, et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
    • (2002) JAMA , vol.288 , pp. 2411-2420
    • Steinhubl, S.R.1    Berger, P.B.2    Mann III, J.T.3
  • 176
    • 27644548513 scopus 로고    scopus 로고
    • Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial
    • COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
    • Chen ZM, Jiang LX, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
    • (2005) Lancet , vol.366 , pp. 1607-1621
    • Chen, Z.M.1    Jiang, L.X.2    Chen, Y.P.3
  • 177
    • 20144373281 scopus 로고    scopus 로고
    • Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    • CLARITY-TIMI 28 Investigators
    • Sabatine MS, Cannon CP, Gibson CM, et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
    • (2005) N Engl J Med , vol.352 , pp. 1179-1189
    • Sabatine, M.S.1    Cannon, C.P.2    Gibson, C.M.3
  • 178
    • 24644495673 scopus 로고    scopus 로고
    • Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study
    • Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators
    • Sabatine MS, Cannon CP, Gibson CM, et al. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224-32.
    • (2005) JAMA , vol.294 , pp. 1224-1232
    • Sabatine, M.S.1    Cannon, C.P.2    Gibson, C.M.3
  • 179
    • 33645861080 scopus 로고    scopus 로고
    • Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    • CHARISMA Investigators
    • Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
    • (2006) N Engl J Med , vol.354 , pp. 1706-1717
    • Bhatt, D.L.1    Fox, K.A.2    Hacke, W.3
  • 180
    • 77449149717 scopus 로고    scopus 로고
    • Platelet adenosine diphosphate P2Y12 receptor antagonism: Benefits and limitations of current treatment strategies and future directions
    • Angiolillo DJ, Ferreiro JL. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev Esp Cardiol 2010; 63: 60-76.
    • (2010) Rev Esp Cardiol , vol.63 , pp. 60-76
    • Angiolillo, D.J.1    Ferreiro, J.L.2
  • 181
    • 46749087824 scopus 로고    scopus 로고
    • Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease
    • Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.
    • (2008) Thromb Haemost , vol.100 , pp. 76-82
    • Serebruany, V.1    Pokov, I.2    Kuliczkowski, W.3    Chesebro, J.4    Badimon, J.5
  • 182
    • 70350056868 scopus 로고    scopus 로고
    • The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy
    • Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 2009; 158: 784.e1-6.
    • (2009) Am Heart J , vol.158 , Issue.784 , pp. 1-6
    • Singla, A.1    Antonino, M.J.2    Bliden, K.P.3    Tantry, U.S.4    Gurbel, P.A.5
  • 183
    • 33745815689 scopus 로고    scopus 로고
    • Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment
    • Angiolillo DJ, Bernardo E, Ramírez C et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006; 48: 298-304.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 298-304
    • Angiolillo, D.J.1    Bernardo, E.2    Ramírez, C.3
  • 184
    • 77649207350 scopus 로고    scopus 로고
    • Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease on dual antiplatelet therapy
    • Angiolillo, DJ, Bernardo E, Capodanno D et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease on dual antiplatelet therapy. J Am Coll Cardiol 2010; 55: 1139-46.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 1139-1146
    • Angiolillo, D.J.1    Bernardo, E.2    Capodanno, D.3
  • 185
    • 65449184492 scopus 로고    scopus 로고
    • Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial)
    • CHARISMA Investigators
    • Dasgupta A, Steinhubl SR, Bhatt DL, et al.; CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 2009; 103: 1359-63.
    • (2009) Am J Cardiol , vol.103 , pp. 1359-1363
    • Dasgupta, A.1    Steinhubl, S.R.2    Bhatt, D.L.3
  • 186
    • 17844373254 scopus 로고    scopus 로고
    • Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents
    • Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents. JAMA 2005; 293: 2126-30.
    • (2005) JAMA , vol.293 , pp. 2126-2130
    • Iakovou, I.1    Schmidt, T.2    Bonizzoni, E.3
  • 187
    • 33645835356 scopus 로고    scopus 로고
    • Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry
    • e-Cypher Investigators
    • Urban P, Gershlick AH, Guagliumi G, et al. e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434-41.
    • (2006) Circulation , vol.113 , pp. 1434-1441
    • Urban, P.1    Gershlick, A.H.2    Guagliumi, G.3
  • 188
    • 33645311266 scopus 로고    scopus 로고
    • Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents
    • Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113: 1108-13.
    • (2006) Circulation , vol.113 , pp. 1108-1113
    • Kuchulakanti, P.K.1    Chu, W.W.2    Torguson, R.3
  • 190
    • 17444444169 scopus 로고    scopus 로고
    • A revised model of platelet aggregation
    • Kulkarni S, Dopheide SM, Yap CL, et al. A revised model of platelet aggregation. J Clin Invest 2000; 105: 783-791.
    • (2000) J Clin Invest , vol.105 , pp. 783-791
    • Kulkarni, S.1    Dopheide, S.M.2    Yap, C.L.3
  • 191
    • 0036764581 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy
    • Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J 2002; 23: 1441-8.
    • (2002) Eur Heart J , vol.23 , pp. 1441-1448
    • Roffi, M.1    Chew, D.P.2    Mukherjee, D.3
  • 192
    • 0035808028 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non- ST-segment-elevation acute coronary syndromes
    • Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non- ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767-71.
    • (2001) Circulation , vol.104 , pp. 2767-2771
    • Roffi, M.1    Chew, D.P.2    Mukherjee, D.3
  • 193
    • 20844448202 scopus 로고    scopus 로고
    • Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel
    • Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators
    • Mehilli J, Kastrati A, Schühlen H, et al. Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627-35.
    • (2004) Circulation , vol.110 , pp. 3627-3635
    • Mehilli, J.1    Kastrati, A.2    Schühlen, H.3
  • 194
    • 33645507439 scopus 로고    scopus 로고
    • Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial
    • Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators
    • Kastrati A, Mehilli J, Neumann FJ et al: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-8.
    • (2006) JAMA , vol.295 , pp. 1531-1538
    • Kastrati, A.1    Mehilli, J.2    Neumann, F.J.3
  • 195
    • 0035927938 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up
    • ADMIRAL Investigators
    • Montalescot G, Barragan P, Wittenberg O, et al. ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. N Engl J Med 2001; 344: 1895-903.
    • (2001) N Engl J Med , vol.344 , pp. 1895-1903
    • Montalescot, G.1    Barragan, P.2    Wittenberg, O.3
  • 196
    • 72949090599 scopus 로고    scopus 로고
    • Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A metaregression analysis of randomized trials
    • De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a metaregression analysis of randomized trials. Eur Heart J 2009; 30: 2705-13.
    • (2009) Eur Heart J , vol.30 , pp. 2705-2713
    • de Luca, G.1    Navarese, E.2    Marino, P.3
  • 197
    • 34547801673 scopus 로고    scopus 로고
    • Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
    • Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1193-204.
    • (2007) Eur Heart J , vol.28 , pp. 1193-1204
    • Rao, S.V.1    Eikelboom, J.A.2    Granger, C.B.3    Harrington, R.A.4    Califf, R.M.5    Bassand, J.P.6
  • 198
    • 33747599590 scopus 로고    scopus 로고
    • Adverse impact of bleeding on prognosis in patients with acute coronary syndromes
    • Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-82.
    • (2006) Circulation , vol.114 , pp. 774-782
    • Eikelboom, J.W.1    Mehta, S.R.2    Anand, S.S.3    Xie, C.4    Fox, K.A.5    Yusuf, S.6
  • 199
    • 33751221316 scopus 로고    scopus 로고
    • Bivalirudin for patients with acute coronary syndromes
    • ACUITY Investigators
    • Stone GW, McLaurin BT, Cox DA, et al. ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-16.
    • (2006) N Engl J Med , vol.355 , pp. 2203-2216
    • Stone, G.W.1    McLaurin, B.T.2    Cox, D.A.3
  • 200
    • 43049160934 scopus 로고    scopus 로고
    • Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: A report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial
    • Feit F, Manoukian SV, Ebrahimi R et al. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2008; 51: 1645-52.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1645-1652
    • Feit, F.1    Manoukian, S.V.2    Ebrahimi, R.3
  • 201
    • 71749092733 scopus 로고    scopus 로고
    • Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention
    • Tavano D, Visconti G, D'Andrea D et al. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol 2009; 104: 1222-8.
    • (2009) Am J Cardiol , vol.104 , pp. 1222-1228
    • Tavano, D.1    Visconti, G.2    D'Andrea, D.3
  • 202
    • 68949092641 scopus 로고    scopus 로고
    • Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction
    • Manoukian SV. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol 2009; 104: 9C-15C.
    • (2009) Am J Cardiol , vol.104
    • Manoukian, S.V.1
  • 203
    • 29244467682 scopus 로고    scopus 로고
    • Influence of aspirin resistance on platelet function profiles in patients on longterm aspirin and clopidogrel after percutaneous coronary intervention
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Influence of aspirin resistance on platelet function profiles in patients on longterm aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006; 97: 38-43.
    • (2006) Am J Cardiol , vol.97 , pp. 38-43
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3
  • 204
    • 36849082996 scopus 로고    scopus 로고
    • The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the aspirin-induced platelet effect (ASPECT) study
    • DiChiara J, Bliden KP, Tantry US et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007; 56: 3014-9.
    • (2007) Diabetes , vol.56 , pp. 3014-3019
    • Dichiara, J.1    Bliden, K.P.2    Tantry, U.S.3
  • 205
    • 77956290748 scopus 로고    scopus 로고
    • Dose comparisons of clopidogrel and aspirin in acute coronary syndromes
    • CURRENT-OASIS 7 Investigators
    • CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-42.
    • (2010) N Engl J Med , vol.363 , pp. 930-942
    • Mehta, S.R.1    Bassand, J.P.2    ChroLavicius, S.3
  • 206
    • 79851495676 scopus 로고    scopus 로고
    • 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease
    • Henry P, Vermillet A, Boval B, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105: 336-44.
    • (2011) Thromb Haemost , vol.105 , pp. 336-344
    • Henry, P.1    Vermillet, A.2    Boval, B.3
  • 207
    • 79959318812 scopus 로고    scopus 로고
    • Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease
    • Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011; 4: 180-7.
    • (2011) Circ Cardiovasc Interv , vol.4 , pp. 180-187
    • Capodanno, D.1    Patel, A.2    Dharmashankar, K.3
  • 208
    • 80052306473 scopus 로고    scopus 로고
    • Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and microor macrovascular complications
    • Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and microor macrovascular complications. Thromb Haemost 2011; 106: 491-9.
    • (2011) Thromb Haemost , vol.106 , pp. 491-499
    • Spectre, G.1    Arnetz, L.2    Östenson, C.G.3    Brismar, K.4    Li, N.5    Hjemdahl, P.6
  • 209
    • 77956922337 scopus 로고    scopus 로고
    • Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes
    • Addad F, Chakroun T, Elalamy I, et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int J Hemato. 2010; 92: 296-301.
    • (2010) Int J Hemato , vol.92 , pp. 296-301
    • Addad, F.1    Chakroun, T.2    Elalamy, I.3
  • 210
    • 33847130538 scopus 로고    scopus 로고
    • Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study
    • Angiolillo DJ, Shoemaker SB, Desai B et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-16.
    • (2007) Circulation , vol.115 , pp. 708-716
    • Angiolillo, D.J.1    Shoemaker, S.B.2    Desai, B.3
  • 211
    • 79952598836 scopus 로고    scopus 로고
    • Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial
    • Price MJ, Berger PB, Teirstein PS, et al. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-105.
    • (2011) JAMA , vol.305 , pp. 1097-1105
    • Price, M.J.1    Berger, P.B.2    Teirstein, P.S.3
  • 212
    • 73949157474 scopus 로고    scopus 로고
    • Platelet thrombin receptor antagonism and atherothrombosis
    • Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010; 31: 17-28.
    • (2010) Eur Heart J , vol.31 , pp. 17-28
    • Angiolillo, D.J.1    Capodanno, D.2    Goto, S.3
  • 213
    • 4944241267 scopus 로고    scopus 로고
    • Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study
    • Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group
    • Neri Serneri GG, Coccheri S, Marubini E, Violi F; Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25: 1845-52.
    • (2004) Eur Heart J , vol.25 , pp. 1845-1852
    • Neri, S.G.G.1    Coccheri, S.2    Marubini, E.3    Violi, F.4
  • 214
    • 0028140168 scopus 로고
    • The Ridogrel Versus Aspirin Patency Trial (RAPT)
    • Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction
    • Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89: 588-95.
    • (1994) Circulation , vol.89 , pp. 588-595
  • 215
    • 33947323564 scopus 로고    scopus 로고
    • Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication
    • Gresele P, Migliacci R, Procacci A, De Monte P, Bonizzoni E. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost 2007; 97: 444-50.
    • (2007) Thromb Haemost , vol.97 , pp. 444-450
    • Gresele, P.1    Migliacci, R.2    Procacci, A.3    de Monte, P.4    Bonizzoni, E.5
  • 216
    • 12144291657 scopus 로고    scopus 로고
    • Evaluation of antiplatelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood
    • Kariyazono H, Nakamura K, Arima J et al. Evaluation of antiplatelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood. Blood Coagul Fibrinolysis 2004; 15: 157-67.
    • (2004) Blood Coagul Fibrinolysis , vol.15 , pp. 157-167
    • Kariyazono, H.1    Nakamura, K.2    Arima, J.3
  • 217
    • 65949110335 scopus 로고    scopus 로고
    • TP receptor antagonism: A new concept in atherothrombosis and stroke prevention
    • Chamorro A. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 2009; 27 Suppl 3: 20-7.
    • (2009) Cerebrovasc Dis , vol.27 , Issue.3 SUPPL. 3 , pp. 20-27
    • Chamorro, A.1
  • 218
    • 80053408596 scopus 로고    scopus 로고
    • The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin
    • Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, Santana Sorensen A. The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. J Thromb Haemost 2011; 9: 2109-11.
    • (2011) J Thromb Haemost , vol.9 , pp. 2109-2111
    • Fontana, P.1    Alberts, P.2    Sakariassen, K.S.3    Bounameaux, H.4    Meyer, J.P.5    Santana, S.A.6
  • 219
    • 79955108369 scopus 로고    scopus 로고
    • Optimizing platelet inhibition in clopidogrel poor metabolizers: Therapeutic options and practical considerations
    • Angiolillo DJ, Ueno M. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations. JACC Cardiovasc Interv 2011; 4: 411-4.
    • (2011) JACC Cardiovasc Interv , vol.4 , pp. 411-414
    • Angiolillo, D.J.1    Ueno, M.2
  • 220
    • 47649116687 scopus 로고    scopus 로고
    • Pharmacology of emerging novel platelet inhibitors
    • Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J. 2008; 156(2 Suppl): S10-5.
    • (2008) Am Heart J , vol.156 , Issue.2 SUPPL.
    • Angiolillo, D.J.1    Capranzano, P.2
  • 221
    • 37349111065 scopus 로고    scopus 로고
    • Prasugrel compared with high loadingand maintenancedose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
    • PRINCIPLE-TIMI 44 Investigators
    • Wiviott SD, Trenk D, Frelinger AL; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loadingand maintenancedose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-32.
    • (2007) Circulation , vol.116 , pp. 2923-2932
    • Wiviott, S.D.1    Trenk, D.2    Frelinger, A.L.3
  • 222
    • 79952149001 scopus 로고    scopus 로고
    • A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
    • Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011; 32: 838-46.
    • (2011) Eur Heart J , vol.32 , pp. 838-846
    • Angiolillo, D.J.1    Badimon, J.J.2    Saucedo, J.F.3
  • 223
    • 36148983750 scopus 로고    scopus 로고
    • Prasugrel versus clopidogrel in patients with acute coronary syndromes
    • TRITON-TIMI 38 Investigators
    • Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-15.
    • (2007) N Engl J Med , vol.357 , pp. 2001-2015
    • Wiviott, S.D.1    Braunwald, E.2    McCabe, C.H.3
  • 224
    • 55949103494 scopus 로고    scopus 로고
    • Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38
    • TRITON-TIMI 38 Investigators
    • Wiviott SD, Braunwald E, Angiolillo DJ, et al.; TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008; 118: 1626-36.
    • (2008) Circulation , vol.118 , pp. 1626-1636
    • Wiviott, S.D.1    Braunwald, E.2    Angiolillo, D.J.3
  • 225
    • 68949092641 scopus 로고    scopus 로고
    • Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction
    • Manoukian SV. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol 2009; 104: 9C-15C.
    • (2009) Am J Cardiol , vol.104
    • Manoukian, S.V.1
  • 226
    • 77951902652 scopus 로고    scopus 로고
    • Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist
    • Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther 2010; 8: 151-8.
    • (2010) Expert Rev Cardiovasc Ther , vol.8 , pp. 151-158
    • Capodanno, D.1    Dharmashankar, K.2    Angiolillo, D.J.3
  • 227
    • 73949112820 scopus 로고    scopus 로고
    • Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study
    • Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-85.
    • (2009) Circulation , vol.120 , pp. 2577-2585
    • Gurbel, P.A.1    Bliden, K.P.2    Butler, K.3
  • 228
    • 35548933800 scopus 로고    scopus 로고
    • Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
    • Storey RF, Husted S, Harrington RA et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-6.
    • (2007) J Am Coll Cardiol , vol.50 , pp. 1852-1856
    • Storey, R.F.1    Husted, S.2    Harrington, R.A.3
  • 229
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
    • for the PLATO Investigators
    • Wallentin L, Becker RC, Budaj A et al. for the PLATO Investigators. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009; 361: 1-13.
    • (2009) N Engl J Med , vol.361 , pp. 1-13
    • Wallentin, L.1    Becker, R.C.2    Budaj, A.3
  • 230
    • 78650368771 scopus 로고    scopus 로고
    • Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
    • James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010; 31: 3006-16.
    • (2010) Eur Heart J , vol.31 , pp. 3006-3016
    • James, S.1    Angiolillo, D.J.2    Cornel, J.H.3
  • 231
    • 70450187946 scopus 로고    scopus 로고
    • Cangrelor: A review on its mechanism of action and clinical development
    • Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009; 7: 1195-201.
    • (2009) Expert Rev Cardiovasc Ther , vol.7 , pp. 1195-1201
    • Ferreiro, J.L.1    Ueno, M.2    Angiolillo, D.J.3
  • 232
    • 0036848824 scopus 로고    scopus 로고
    • Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
    • Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13: 407-13.
    • (2002) Platelets , vol.13 , pp. 407-413
    • Storey, R.F.1    Wilcox, R.G.2    Heptinstall, S.3
  • 233
    • 71849087338 scopus 로고    scopus 로고
    • Platelet Inhibition with Cangrelor in Patients Undergoing PCI
    • Harrington RA, Stone GW, McNulty S et al. Platelet Inhibition with Cangrelor in Patients Undergoing PCI. N Engl J Med 2009; 361: 2318-29.
    • (2009) N Engl J Med , vol.361 , pp. 2318-2329
    • Harrington, R.A.1    Stone, G.W.2    McNulty, S.3
  • 234
    • 71849119604 scopus 로고    scopus 로고
    • Intravenous Platelet Blockade with Cangrelor during PCI
    • the CHAMPION PLATFORM Investigators
    • Bhatt DL, Lincoff AM, Gibson CM, et al. the CHAMPION PLATFORM Investigators. Intravenous Platelet Blockade with Cangrelor during PCI. N Engl J Med 2009; 361: 2330-41.
    • (2009) N Engl J Med , vol.361 , pp. 2330-2341
    • Bhatt, D.L.1    Lincoff, A.M.2    Gibson, C.M.3
  • 235
    • 70649090353 scopus 로고    scopus 로고
    • Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a directacting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot
    • trial
    • Berger JS, Roe MT, Gibson CM et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a directacting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009; 158: 998-1004.
    • (2009) Am Heart J , vol.158 , pp. 998-1004
    • Berger, J.S.1    Roe, M.T.2    Gibson, C.M.3
  • 236
    • 77954510334 scopus 로고    scopus 로고
    • Elinogrel: Pharmacological principles, preclinical and early phase clinical testing
    • Ueno M, Rao SV, Angiolillo DJ. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol 2010; 6: 445-53.
    • (2010) Future Cardiol , vol.6 , pp. 445-453
    • Ueno, M.1    Rao, S.V.2    Angiolillo, D.J.3
  • 237
    • 77955677366 scopus 로고    scopus 로고
    • Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12) receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)
    • Leonardi S, Rao SV, Harrington RA et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12) receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 2010; 160: 65-72.
    • (2010) Am Heart J , vol.160 , pp. 65-72
    • Leonardi, S.1    Rao, S.V.2    Harrington, R.A.3
  • 239
    • 79961056489 scopus 로고    scopus 로고
    • Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy
    • Angiolillo DJ, Capranzano P, Ferreiro JL, et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011; 106: 253-62.
    • (2011) Thromb Haemost , vol.106 , pp. 253-262
    • Angiolillo, D.J.1    Capranzano, P.2    Ferreiro, J.L.3
  • 240
    • 52449085759 scopus 로고    scopus 로고
    • A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study
    • Angiolillo DJ, Capranzano P, Goto S et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008; 29: 2202-11.
    • (2008) Eur Heart J , vol.29 , pp. 2202-2211
    • Angiolillo, D.J.1    Capranzano, P.2    Goto, S.3
  • 241
    • 62549101321 scopus 로고    scopus 로고
    • Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study
    • Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101-9.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 1101-1109
    • Jeong, Y.H.1    Lee, S.W.2    Choi, B.R.3
  • 242
    • 84655161920 scopus 로고    scopus 로고
    • Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus
    • Ferreiro JL, Ueno M, Desai B, Capranzano P, Capodanno D, Angiolillo DJ. Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. Rev Esp Cardiol 2012; 65: 105-6.
    • (2012) Rev Esp Cardiol , vol.65 , pp. 105-106
    • Ferreiro, J.L.1    Ueno, M.2    Desai, B.3    Capranzano, P.4    Capodanno, D.5    Angiolillo, D.J.6
  • 243
    • 27844463244 scopus 로고    scopus 로고
    • Coronary stent restenosis in patients treated with cilostazol
    • Cilostazol for Restenosis Trial (CREST) Investigators
    • Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005; 112: 2826-32.
    • (2005) Circulation , vol.112 , pp. 2826-2832
    • Douglas Jr., J.S.1    Holmes Jr., D.R.2    Kereiakes, D.J.3    Grines, C.L.4    Block, E.5    Ghazzal, Z.M.6
  • 244
    • 27644555633 scopus 로고    scopus 로고
    • Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis
    • Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005; 46: 1833-7.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 1833-1837
    • Lee, S.W.1    Park, S.W.2    Hong, M.K.3    Kim, Y.H.4    Lee, B.K.5    Song, J.M.6
  • 245
    • 44349138210 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
    • Biondi-Zoccai GG, Lotrionte M, Anselmino M, Moretti C, Agostoni P, Testa L, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J. 2008; 155: 1081-9.
    • (2008) Am Heart J , vol.155 , pp. 1081-1089
    • Biondi-Zoccai, G.G.1    Lotrionte, M.2    Anselmino, M.3    Moretti, C.4    Agostoni, P.5    Testa, L.6
  • 246
    • 84860390388 scopus 로고    scopus 로고
    • Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel
    • Ueno M, Ferreiro JL, Tomasello SD, et al. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. JACC Cardiovasc Interv 2011; 4: 905-12.
    • (2011) JACC Cardiovasc Interv , vol.4 , pp. 905-912
    • Ueno, M.1    Ferreiro, J.L.2    Tomasello, S.D.3
  • 247
    • 47649113839 scopus 로고    scopus 로고
    • Clinical overview of promising nonthienopyridine antiplatelet agents
    • Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J 2008; 156: S23-8.
    • (2008) Am Heart J , vol.156
    • Angiolillo, D.J.1    Guzman, L.A.2
  • 248
    • 77955219114 scopus 로고    scopus 로고
    • Mechanism of action and clinical development of platelet thrombin receptor antagonists
    • Ueno M, Ferreiro JL, Angiolillo DJ. Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Rev Cardiovasc Ther 2010; 8: 1191-200.
    • (2010) Expert Rev Cardiovasc Ther , vol.8 , pp. 1191-1200
    • Ueno, M.1    Ferreiro, J.L.2    Angiolillo, D.J.3
  • 249
    • 73949157474 scopus 로고    scopus 로고
    • Platelet thrombin receptor antagonism and atherothrombosis
    • Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010; 31: 17-28.
    • (2010) Eur Heart J , vol.31 , pp. 17-28
    • Angiolillo, D.J.1    Capodanno, D.2    Goto, S.3
  • 250
    • 61849180442 scopus 로고    scopus 로고
    • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study
    • TRA-PCI Investigators
    • Becker RC, Moliterno DJ, Jennings LK et al.; TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-28.
    • (2009) Lancet , vol.373 , pp. 919-928
    • Becker, R.C.1    Moliterno, D.J.2    Jennings, L.K.3
  • 251
    • 68949156886 scopus 로고    scopus 로고
    • Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial
    • TRA 2(o)P-TIMI 50 Investigators
    • Morrow DA, Scirica BM, Fox KA, et al. TRA 2(o)P-TIMI 50 Investigators. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009; 158: 335-41.
    • (2009) Am Heart J , vol.158 , pp. 335-341
    • Morrow, D.A.1    Scirica, B.M.2    Fox, K.A.3
  • 252
    • 83655177669 scopus 로고    scopus 로고
    • Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
    • TRACER Investigators
    • Tricoci P, Huang Z, Held C, et al. TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
    • (2012) N Engl J Med , vol.366 , pp. 20-33
    • Tricoci, P.1    Huang, Z.2    Held, C.3
  • 253
    • 77949912887 scopus 로고    scopus 로고
    • New oral anticoagulants: A practical guide for clinicians
    • Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 2010; 29: 182-91.
    • (2010) J Thromb Thrombolysis , vol.29 , pp. 182-191
    • Wittkowsky, A.K.1
  • 254
    • 80054733922 scopus 로고    scopus 로고
    • RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
    • RUBY-1 Investigators
    • Steg PG, Mehta SR, Jukema JW, et al. RUBY-1 Investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011; 32: 2541-54.
    • (2011) Eur Heart J , vol.32 , pp. 2541-2554
    • Steg, P.G.1    Mehta, S.R.2    Jukema, J.W.3
  • 255
    • 80052162121 scopus 로고    scopus 로고
    • Apixaban with antiplatelet therapy after acute coronary syndrome
    • Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708.
    • (2011) N Engl J Med , vol.365 , pp. 699-708
    • Alexander, J.H.1    Lopes, R.D.2    James, S.3
  • 256
    • 84862907587 scopus 로고    scopus 로고
    • Rivaroxaban in patients with a recent acute coronary syndrome
    • ATLAS ACS 2-TIMI 51 Investigators
    • Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19.
    • (2012) N Engl J Med , vol.366 , pp. 9-19
    • Mega, J.L.1    Braunwald, E.2    Wiviott, S.D.3
  • 257
    • 69949096467 scopus 로고    scopus 로고
    • Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): A randomised, double-blind, active-controlled, phase 2 trial
    • Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009; 374: 787-95.
    • (2009) Lancet , vol.374 , pp. 787-795
    • Sabatine, M.S.1    Antman, E.M.2    Widimsky, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.